Arcus Biosciences, Inc. (RCUS), a clinical-stage, global biopharmaceutical company, Tuesday announced an underwritten offering of 13,636,364 common shares at $11.00 per share, aiming to raise about $150 million before expenses.
Shares of Arcus Bioscience are dropping by 5% in the pre-market trading.
All shares are being offered by the company, and the offering is expected to close around February 19.
Arcus plans to use the funds from the offering for research and development, including the clinical development of casdatifan, manufacturing costs, and general corporate needs like working capital and operating expenses.
In the pre-market trading, Arcus Biosciences is 4.05% lesser at $12.57 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.